Open Access Pub publishes peer-reviewed, free-to-read open-access articles. Showing
articles matching foci — open any to read the full text,
or download the PDF or XML.
Jan 2019 DOI 10.14302/issn.2690-6759.jpar-18-2510
MA Khalifa RefaatCorresponding author
Medical Parasitology Department, Faculty of Medicine, Assiut University
Bancroftian filariasis (BF) is a debilitating disease that has plagued Egypt since the time of the pharaohs. Egypt is the first large endemic country in the world to reach the five-year mark in its national campaign. Now that the mass treatments are completed, a follow-up epidemiological assessment will reveal whether this large-scale, pioneering campaign has been successful in finally eliminating the disease. Hence the aim of the present work was to detect the prevalence of bancoftian filariasis in Tema, El-Maragha, Akhmeem and Girga districts in Sohag Governorate, Upper Egypt. Finger prick thick blood films were randomly collected from 500 clinically suspected individuals representing different sexes and ages suffering from lower limb non-pitting edema and/or inguinal lymphadenitis from May 2015 to February 2017. Three patients (0.6%) were infected with microfilariae of Wuchereria bancrofti while one chronic case was detected with severe chronic elephantiasis that was amicrofilaraemic but was confirmed serologically. Results were discussed in regards of age, gender, occupation, locality and residence. It was concluded that bancroftian filariasis is still endemic in three districts (Tema, El- maragha and Girga). Although in sporadic few cases, the problem should be taken seriously as one microfilaramic patient could be a patent reservoir for spreading of the disease through infecting the prevailing Culex pipiense mosquito intermediate host.
Jul 2020 DOI 10.14302/issn.2575-1212.jvhc-20-3434
R.R. Moreira PamelaCorresponding author
Background The mammary glands are the second most common tumor development site in female dogs. One of the ways of staging such tumors is to evaluate the presence or absence of distant metastasis, including in bone marrow. Such findings in human medicine are associated with poor survival of women with breast tumors. However, in veterinary medicine, this clinical staging is used more for patients with lymphomas and mastocytomas. Studies using bone marrow biopsies as a staging method for mammary tumors are scarce. Objectives The present study was to evaluate mammary lesions and bone marrow in 23 female dogs, searching for disseminated tumor cells or metastatic foci. Results: Grade I carcinoma in mixed tumors was the type most observed (22.4%), and there was no statistical difference in relation to tumor size or presence of metastasis in lymph nodes. In the bone marrow of one female dog with carcinosarcoma (4.35%), there was cytoplasmic marking of a probable disseminated tumor cell of epithelial origin, and immunohistochemical evaluation showed presence of cytokeratin-19 antibodies. None of the female dogs presenting reduced cellularity or medullary fibrosis, confirmed through Masson’s trichrome technique, had cell marking in immunohistochemical analyses. Conclusions Bone marrow evaluation can be used as a staging method for mammary gland tumors in female dogs, since disseminated tumor cells present the potential to become secondary lesions and to disseminate to distant foci, thereby causing tertiary metastases over an indeterminate period of time.
Jun 2016 DOI 10.14302/issn.2329-9487.jhc-16-931
F.Babbs CharlesCorresponding author
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA
Background: This brief report presents a potential new technique for locating the sites of origin of focal atrial tachycardias from standard 12-lead electrocardiograms. Methods: Estimated P wave vector coordinates are derived from leads I, aVF, V1 and V2, and mapped to a three dimensional coordinate system in space. A simple graphical method is used to find the back projection of the P wave vector onto the surface of atrial muscle to estimate the most likely site of origin of the tachycardia. Results: Graphical back projection correctly identified foci of atrial tachycardias in 19 of 19 cases described in the most complete available published study. Conclusions: Clinical studies are indicated to validate this simple method for initial noninvasive evaluation of candidates for ablation therapy.
Aug 2014 DOI 10.14302/issn.2329-9487.jhc-13-313
A. Hammond DraytonCorresponding author
University of Arkansas for Medical Sciences, Little Rock, Arkansas
Objective: Ablation of foci within the atria has been shown to resolve symptoms of atrial fibrillation and atrial flutter. However, no standard has been established for anticoagulation after the procedure. Enoxaparin has been well described in the literature as a means to provide anticoagulation after ablation procedures. The only enoxaparin doses previously studied were 0.5 mg/kg and 1 mg/kg, both given every 12 hours. The purpose of the study was to compare the incidence of a major bleed or vascular complication in patients who received enoxaparin doses between 0.5 mg/kg and 1 mg/kg every 12 hours with patients who received either 0.5 mg/kg or 1 mg/kg every 12 hours. Methods: This IRB-approved, single-center, retrospective, cohort study included subjects greater than 18 years of age who received an atrial fibrillation or atrial flutter ablation procedure and at least one dose of enoxaparin post-ablation. Results: There were 119 subjects who satisfied the inclusion criteria. The primary outcome, incidence of major bleeding or vascular complication, did not demonstrate a statistically significant difference between groups (p = 0.92). The incidences were 4.8% with enoxaparin ≥ 1 mg/kg, 3% with enoxaparin between 0.5 mg/kg and 1 mg/kg, and 3.2% with enoxaparin ≤ 0.5 mg/kg. No subject experienced an ischemic stroke or transient ischemic attack within 28 days of a cardiac ablation procedure. Conclusion: Significant increases in major bleeding or vascular complications may not exist with an intermediate dose of enoxaparin provided after a cardiac ablation procedure.